Table 1 Baseline characteristics.
Total | High MELD-XI (≥ 14) | Low MELD-XI (< 14) | p value | |
|---|---|---|---|---|
n = 172 | n = 51 | n = 121 | ||
Age (years) | 77.3 ± 7.3 | 79.1 ± 6.3 | 76.6 ± 7.5 | 0.04 |
Male, n (%) | 67 (39.0) | 27 (52.9) | 40 (33.1) | 0.02 |
BMI (kg/m2) | 26.0 ± 5.2 | 26.1 ± 5.0 | 26.0 ± 5.3 | 0.89 |
Diabetes, n (%) | 48 (27.9) | 17 (33.3) | 31 (25.6) | 0.30 |
Hypertension, n (%) | 149 (86.6) | 46 (90.2) | 103 (85.1) | 0.37 |
CAD, n (%) | 95 (55.2) | 32 (62.8) | 63 (52.1) | 0.20 |
Prior CABG, n (%) | 41 (23.8) | 14 (27.5) | 27 (22.3) | 0.47 |
Prior valve intervention, n (%) | 68 (39.5) | 22 (43.1) | 46 (38.0) | 0.53 |
Previous myocardial infarction, n (%) | 46 (26.7) | 11 (21.6) | 35 (28.9) | 0.32 |
Previous stroke, n (%) | 24 (14.0) | 8 (15.7) | 16 (13.2) | 0.67 |
Atrial fibrillation, n (%) | 159 (92.4) | 48 (94.1) | 111 (91.7) | 0.69 |
NYHA functional class | 0.99 | |||
II, n (%) | 23 (13.4) | 7 (13.7) | 16(13.2) | |
III, n (%) | 118 (68.6) | 35 (68.6) | 83 (68.6) | |
IV, n (%) | 31 (18.0) | 9 (17.7) | 22 (18.2) | |
Lead across tricuspid valve, n (%) | 55 (32.0) | 18 (35.3) | 37 (30.6) | 0.54 |
COPD, n (%) | 40 (23.3) | 12 (23.5) | 28 (23.1) | 0.96 |
Logistic EuroSCORE (%) | 15.1 [8.2, 26.6] | 17.9 [8.9, 30.9] | 14.7 [7.9, 23.7] | 0.20 |
NT-pro BNP (pg/ml) | 1838 [1006, 3726] | 3264 [2153, 7185] | 1584 [906, 2561] | < 0.0001 |
Medication at baseline | ||||
Beta-blocker, n (%) | 147 (85.5) | 46 (90.2) | 101 (83.5) | 0.24 |
RAS inhibitor, n (%) | 113 (65.7) | 30 (58.8) | 83 (68.6) | 0.36 |
Loop diuretics, n (%) | 162 (94.2) | 49 (96.1) | 113 (93.4) | 0.27 |
Standardized furosemide equivalent (mg/day) | 40 [20, 80] | 40 [20, 150] | 30 [20, 80] | 0.01 |
Aldosterone antagonist, n (%) | 79 (45.9) | 25 (49.0) | 54 (42.1) | 0.64 |
